ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

In EU first, Sinopharm's coronavirus vaccine approved by Hungary

Country seals deal for 5m doses of Chinese-developed shot

Hungary became the European Union's first member to approve China's Sinopharm COVID-19 vaccine.   © Reuters

BUDAPEST (Reuters) -- Hungary became the European Union's first member to approve China's Sinopharm COVID-19 vaccine, sealing a deal on Friday for 5 million doses just a week after becoming the first EU member to buy Russia's Sputnik V vaccine.

Prime Minister Viktor Orban, whose nationalist government frequently bucks the consensus of its EU neighbors, said he would personally opt to receive the Chinese vaccine, as he trusted it more than others.

The announcement came a day after Hungary's government issued a decree calling for a green light for any vaccine that had been administered to at least 1 million people in at least three other countries.

China has been heavily marketing its two coronavirus vaccines, made by Sinopharm and Sinovac, with millions of doses shipped around the world to developing countries, particularly in Asia and Latin America.

Meanwhile, EU countries, relying so far almost entirely on a vaccine from Pfizer, have fallen far behind Britain, the United States and a number of developing countries in rolling out vaccines.

Hours earlier, Hungary's drug regulator gave emergency use approval to the Sinopharm vaccine, rather than wait for the bloc's European Medicines Agency (EMA) to give the go-ahead, adding it to a list that also includes the Pfizer, Moderna and AstraZeneca vaccines as well as Russia's Sputnik-V shot.

Foreign Minister Peter Szijjarto said the Sinopharm vaccines were enough to inoculate 2.5 million people, or about a quarter of its population, delivered in four batches over four months.

Premier Orban said the government monitored inoculations using the Chinese vaccine in neighboring Serbia.

However, the Hungarian Medical Chamber (MOK) warned Budapest should continue "to follow drug safety rules in a transparent manner and only approve marketing of products after a review respecting European Medicines Agency rules".

The Chamber could not immediately be reached for further comment. The government declined immediate comment.

Asked whether it had completed its study before authorizing the vaccine, the drug regulator OGYEI said it gave the green light because the shot fit the conditions in the government decree. It said it would continue to keep track of the vaccine.

It said that another state organization, the National Public Health Centre, would put each vaccine shipment through tests, adding that 16 million people worldwide had already received the Sinopharm jab safely.

In Hungary, which has close to 10 million people, 364,909 people have been infected and 12,374 people have died of COVID-19 so far. The government has extended restrictions until March 1, including an 8 pm curfew and the closure of restaurants.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more